2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132583E
    FAM labled IONIS-DNM2-2.5Rx sodium 98%
    FAM labled IONIS-DNM2-2.5Rx sodiumis a FAM labled IONIS-DNM2-2.5Rx sodium.
    FAM labled IONIS-DNM2-2.5Rx sodium
  • HY-132583H
    Cy3 labled IONIS-DNM2-2.5Rx sodium 98%
    Cy3 labled IONIS-DNM2-2.5Rx sodium is a Cy3 labled IONIS-DNM2-2.5Rx sodium.
    Cy3 labled IONIS-DNM2-2.5Rx sodium
  • HY-132587C
    Fitusiran sodium scrambled negative control 98%
    Fitusiran sodium scrambled negative control is the sequence scrambled negative control of Fitusiran sodium. Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
    Fitusiran sodium scrambled negative control
  • HY-132587D
    FAM labled Fitusiran sodium 98%
    FAM labled Fitusiran sodiumis a FAM labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
    FAM labled Fitusiran sodium
  • HY-132587E
    Cy3 labled Fitusiran sodium 98%
    Cy3 labled Fitusiran sodium is a Cy3 labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
    Cy3 labled Fitusiran sodium
  • HY-132591C
    Inclisiran sodium scrambled negative control 98%
    Inclisiran sodium scrambled negative control is the sequence scrambled negative control of Inclisiran sodium.
    Inclisiran sodium scrambled negative control
  • HY-132591D
    FAM labled Inclisiran sodium 98%
    FAM labled Inclisiran sodiumis a FAM labled Inclisiran sodium.
    FAM labled Inclisiran sodium
  • HY-132591E
    Cy3 labled Inclisiran sodium 98%
    Cy3 labled Inclisiran sodium is a Cy3 labled Inclisiran sodium.
    Cy3 labled Inclisiran sodium
  • HY-13463BS
    Avatrombopag-d8 hydrochloride 98%
    Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.
    Avatrombopag-d8 hydrochloride
  • HY-135328S
    Norverapamil-d7 263175-44-6 98%
    Norverapamil-d7 is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.
    Norverapamil-d7
  • HY-135356R
    m-Nifedipine (Standard) 21881-77-6 98%
    m-Nifedipine (Standard) is the analytical standard of m-Nifedipine. This product is intended for research and analytical applications. m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
    m-Nifedipine (Standard)
  • HY-135380R
    Atorvastatin acetonide tert-butyl ester (Standard) 125971-95-1 99.76%
    Atorvastatin acetonide tert-butyl ester (Standard) is the analytical standard of Atorvastatin acetonide tert-butyl ester. This product is intended for research and analytical applications. Atorvastatin acetonide tert-butyl ester is a useful pharmaceutical intermediate in the preparation of Atorvastatin salts. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.
    Atorvastatin acetonide tert-butyl ester (Standard)
  • HY-135405R
    4-Acetylsimvastatin (Standard) 145576-25-6
    4-Acetylsimvastatin (Standard) is the analytical standard of 4-Acetylsimvastatin. This product is intended for research and analytical applications. 4-Acetylsimvastatin is an acetylated simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    4-Acetylsimvastatin (Standard)
  • HY-135746R
    OR-1896 (Standard) 220246-81-1
    7-epi-Taxol (Standard) is the analytical standard of 7-epi-Taxol. This product is intended for research and analytical applications. 7-epi-Taxol is an active metabolite of taxol, with activity comparable to that of taxol against cell replication, promoting microtubule bundle formation and against microtubule depolymerization.
    OR-1896 (Standard)
  • HY-135746S
    OR-1896-d3
    OR-1896-d3 is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation.
    OR-1896-d3
  • HY-135910R
    3,4-Dehydro Cilostazol (Standard) 73963-62-9 98%
    3,4-Dehydro Cilostazol (Standard) is the analytical standard of 3,4-Dehydro Cilostazol. This product is intended for research and analytical applications. 3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study.
    3,4-Dehydro Cilostazol (Standard)
  • HY-13599S3
    Cladribine-13C3,15N3
    Cladribine-13C3,15N3 (2-Chloro-2′-deoxyadenosine-13C3,15N3) is the 13C- and 15N-labeled Cladribine (HY-13599). Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
    Cladribine-13C3,15N3
  • HY-13599S4
    Cladribine-13C,15N2
    Cladribine-13C,15N2 (2-Chloro-2′-deoxyadenosine-13C,15N2) is the 13C- and 15N-labeled Cladribine (HY-13599). Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active?adenosine deaminase?inhibitor. Cladribine functions as an inhibitor of?DNA synthesis?to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.
    Cladribine-13C,15N2
  • HY-136346S
    Ortho-hydroxy atorvastatin lactone-d5 265989-50-2 98%
    Ortho-hydroxy atorvastatin lactone-d5 is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.
    Ortho-hydroxy atorvastatin lactone-d5
  • HY-136347R
    3α-Hydroxy pravastatin sodium (Standard) 81093-43-8
    3α-Hydroxy pravastatin sodium (Standard) is the analytical standard of 3α-Hydroxy pravastatin sodium. This product is intended for research and analytical applications. 3α-Hydroxy pravastatin sodium is the major metabolite of Pravastatin (HY-B0165A). Pravastatin is a competitive HMG-CoA reductase inhibitor.
    3α-Hydroxy pravastatin sodium (Standard)
Cat. No. Product Name / Synonyms Application Reactivity